How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

An international team of quantum researchers has shown how machine learning can be used to filter a practically infinite ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Euclidean Technologies Management receives an Average Parent rating. The Parent Pillar assessment is based on a structured evaluation of key factors that influence a firm's ability to support strong ...